Unknown PHASE4 INTERVENTIONAL 2-arm NCT05863832

Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole (CIPRO-001)

Single Center, Open Label, Controlled Study to Assess the Safety & Efficacy of Oral Ciprodiazole Versus Currently Used Ciprofloxacin & Metronidazole Tablets in Pelvi-abdominal Infections and Following IV Antibiotics in Post-operative Period

Sponsor: MinaPharm Pharmaceuticals

Conditions Surgical Site Infections

Interventions Ciprodiazole Ciprofloxacin Tablets & Metronidazole tablets

Updated 5 times since 2023 Last updated: May 8, 2023 Started: Aug 17, 2021 Primary completion: Dec 31, 2023 Completion: Dec 31, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05863832, this PHASE4 trial focuses on Surgical Site Infections and remains ongoing. Sponsored by MinaPharm Pharmaceuticals, it has been updated 5 times since 2021, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE4
May 2025 — Sep 2025 [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — May 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Jun 2023 — Jul 2024 [monthly]

Recruiting PHASE4

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MinaPharm Pharmaceuticals

Data source: MinaPharm Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shibīn al Kawm, Egypt